Medicare Enrolled
Dr. Benson Chin, MD
Family Medicine · Yuba City, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chin
Dr. Benson Chin is a family medicine specialist in Yuba City, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Chin performed 6,053 Medicare services across 1,119 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chin received a total of $14,988 from 57 pharmaceutical and/or device companies across 889 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in family medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 3% volume in CA
$14,988 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,053
Medicare services
Top 3% in CA for family medicine
1,119
Unique beneficiaries
$38
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~319 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,500 | $18 | $33 |
| Acupuncture with electrical stimulation, each additional 15 minutes This code represents an additional 15-minute unit of acupuncture treatment that includes the application of electrical stimulation. |
974 | $30 | $80 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
821 | $92 | $250 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
709 | $68 | $200 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
498 | $11 | $100 |
| Acupuncture with electrical stimulation, initial 15 minutes This procedure involves inserting needles into specific points on the body and applying mild electrical currents to stimulate them. It is performed for the first 15 minutes of the treatment session. |
487 | $37 | $69 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
432 | $1 | $10 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
156 | $1 | $10 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
87 | $32 | $70 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
83 | $72 | $150 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
51 | $3 | $30 |
| Blood glucose test using hand-held instrument A test that measures the level of sugar in the blood using a portable device. The result helps monitor blood glucose levels. |
35 | $3 | $50 |
| Stool test for blood to screen for colon tumors A test that analyzes a stool sample to detect hidden blood, which is used to screen for colon tumors. |
34 | $4 | $40 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
34 | $12 | $125 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
32 | $135 | $250 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
28 | $22 | $145 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
27 | $78 | $300 |
| Skin biopsy, tangential A procedure to remove a sample of the first identified skin growth for laboratory examination. |
26 | $77 | $200 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
15 | $120 | $350 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
13 | $217 | $300 |
| Punch biopsy of first skin growth A small, circular piece of skin is removed from a skin growth using a circular blade. The sample is then sent to a laboratory for examination. |
11 | $98 | $300 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$14,988
Total received (2018-2024)
Avg $2,141/year across 7 years
Top 2% in CA for family medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
57
Companies
889
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,988 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,716
2023
$2,626
2022
$2,277
2021
$2,346
2020
$2,078
2019
$1,893
2018
$2,052
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$558
ABBVIE INC.
$276
AstraZeneca Pharmaceuticals LP
$216
Mylan Specialty L.P.
$112
GlaxoSmithKline, LLC.
$99
Bayer Healthcare Pharmaceuticals Inc.
$69
Otsuka America Pharmaceutical, Inc.
$59
Lilly USA, LLC
$56
PFIZER INC.
$53
Daiichi Sankyo Inc.
$39
Novartis Pharmaceuticals Corporation
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$29
Novo Nordisk Inc
$25
SANOFI PASTEUR INC.
$24
Xeris Pharmaceuticals, Inc.
$23
Dexcom, Inc.
$21
Radius Health, Inc.
$15
Optinose US, Inc.
$13
Top 3 companies account for 61.2% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$2,579
AbbVie Inc.
$1,110
AstraZeneca Pharmaceuticals LP
$1,103
Amarin Pharma Inc.
$991
ABBVIE INC.
$775
ARBOR PHARMACEUTICALS, INC.
$728
Boehringer Ingelheim Pharmaceuticals, Inc.
$580
GlaxoSmithKline, LLC.
$568
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$559
Novo Nordisk Inc
$458
Lilly USA, LLC
$428
Otsuka America Pharmaceutical, Inc.
$412
Allergan Inc.
$407
Corcept Therapeutics
$391
Janssen Pharmaceuticals, Inc
$384
SANOFI-AVENTIS U.S. LLC
$287
Takeda Pharmaceuticals U.S.A., Inc.
$278
PFIZER INC.
$248
Sunovion Pharmaceuticals Inc.
$225
Arbor Pharmaceuticals, Inc.
$191
Mylan Specialty L.P.
$187
Medtronic Vascular, Inc.
$159
Eisai Inc.
$131
Radius Health, Inc.
$124
Alcon Laboratories Inc
$122
Novartis Pharmaceuticals Corporation
$112
Merck Sharp & Dohme Corporation
$107
SANOFI PASTEUR INC.
$92
Teva Pharmaceuticals USA, Inc.
$87
Xeris Pharmaceuticals, Inc.
$81
Almatica Pharma LLC
$80
IDORSIA PHARMACEUTICALS US INC
$74
Bayer Healthcare Pharmaceuticals Inc.
$69
Optinose US, Inc.
$61
Kowa Pharmaceuticals America, Inc.
$56
Allergan, Inc.
$49
Merck Sharp & Dohme LLC
$49
Biohaven Pharmaceuticals, Inc.
$47
Harmony Biosciences LLC
$46
Biohaven Pharmaceutical Holding Company Ltd.
$43
Abbott Laboratories
$43
Daiichi Sankyo Inc.
$39
Esperion Therapeutics, Inc.
$39
Hologic, LLC
$37
Astellas Pharma US Inc
$35
Indivior Inc.
$35
E.R. Squibb & Sons, L.L.C.
$34
Genentech USA, Inc.
$33
Sanofi Pasteur Inc.
$31
RedHill Biopharma Inc.
$29
Lundbeck LLC
$25
Grifols USA, LLC
$24
Azurity Pharmaceuticals, Inc.
$24
Alfasigma USA, Inc.
$21
Dexcom, Inc.
$21
Bausch Health US, LLC
$20
Otsuka Pharmaceutical Development & Commercialization, Inc.
$18
Top 3 companies account for 32.0% of all-time payments
Associated products mentioned in payments ›
ABILIFY MAINTENA · ABILIFY MYCITE · AC2 · ADACEL · AIRSUPRA · AJOVY · ANORO ELLIPTA · APLENZIN · Aimovig · Amitiza · Aptima Combo 2 · BELSOMRA · BEXSERO · BREZTRI · BREZTRI AEROSPHERE · BYDUREON · CHANTIX · CREON · DAILIES · Dayvigo · Dexcom G6 Transmitter · ELIQUIS · EMGALITY · EUCRISA · EVENITY · EVUSHELD · Edarbi · Edarbyclor · Evekeo · Evekeo ODT · FARXIGA · FASENRA · FLUZONE HIGH-DOSE · FLUZONE QUADRIVALENT · FLUZONE QUADRIVALENT NORTHERN HEMISPHERE · FORTEO · FreeStyle Libre 2 · GARDASIL 9 · GATTEX · GLASSIA · GRALISE · GVOKE HYPOPEN · Horizant · INJECTAFER · INVOKANA · JANUVIA · JARDIANCE · Kerendia · Korlym · LATUDA · LEQVIO · LINZESS · LONHALA MAGNAIR · LOREEV XR · LYRICA · Livalo · MENACTRA · MENVEO · MOUNJARO · MYRBETRIQ · Motegrity · Movantik · NEXLETOL · NURTEC ODT · Otezla · Ozempic · PREVNAR 13 · PREVNAR 20 · Prolastin-C Liquid · Prolia · QULIPTA · QUVIVIQ · RECORLEV · REXULTI · RYBELSUS · Repatha · Rybelsus · SAPHRIS · SHINGRIX · SOLIQUA 100/33 · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUBLOCADE · SYMBICORT · Saxenda · TOUJEO · TRELEGY ELLIPTA · TRINTELLIX · TRULICITY · Tresiba · Trintellix · TurboHawk · Tymlos · UBRELVY · Utibron · VIBERZI · VIIBRYD · VRAYLAR · Vascepa · Victoza · WAKIX · XARELTO · XIFAXAN · Xhance · Xofluza · YUPELRI · Yupelri · Zelnorm
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 2% for family medicine in CA.
Geographic Context
Family medicine physicians within 10 mi
106
Per 100K population
107.1
County median income
$75,450
Nearest hospital
SUTTER SURGICAL HOSPITAL - NORTH VALLEY
5.9 mi
5.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chin is a clinical cardiology specialist, with above-average Medicare volume (top 3% in CA), with low-engagement industry engagement in the top 2% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chin experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Chin performed 1,500 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chin receive payments from pharmaceutical companies?
Yes. Dr. Chin received a total of $14,988 from 57 companies across 889 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chin's costs compare to other family medicine physicians in Yuba City?
Dr. Chin's average Medicare payment per service is $38. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Family Medicine
Common procedures, typical costs, and what industry payments mean in family medicine.
Same specialty & city
Family Medicine Physicians in Yuba City
Browse family medicine physicians in Yuba City ranked by procedure volume and transparency data.
Highest volume
Top Family Medicine Physicians in CA
Family medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Family Medicine Physicians in CA
Which CA family medicine physicians receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology